Helus Pharma

Helus Pharma is a biopharmaceutical company focused on developing next-generation treatments for mental health. Its mission is to help minds heal by pursuing therapies intended to foster durable improvements in mental health. The company’s research centers on novel serotonergic agonists, synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Through a proprietary drug development platform, Helus is advancing two lead programs, HLP003 and HLP004, and reports more than 350 pending patent applications and over 100 granted patents.

Helus also develops proprietary drug delivery systems and aims to create formulations that support consistent administration, reduce variation in acute effects among individuals, and potentially shorten time in clinic. Its work includes clinical trials, pipeline development, intellectual property, and scientific publications. The company reports completing enrollment in a Phase 2 study evaluating CYB004 for generalized anxiety disorder. Helus’s team brings pharmaceutical development, regulatory, and neuropsychiatry experience to its programs. The company is listed on Nasdaq and Cboe Canada under the ticker HELP and shares updates, investor information, and career opportunities through its website.